John Mantsch
Corporate Officer/Principal bei Marquette University
Aktive Positionen von John Mantsch
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Marquette University | Corporate Officer/Principal | - | - |
Karriereverlauf von John Mantsch
Ehemalige bekannte Positionen von John Mantsch
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Gründer | 01.01.2007 | - |
Ausbildung von John Mantsch
| Louisiana State University Shreveport | Doctorate Degree |
| Allegheny College | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Founder | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |
- Börse
- Insiders
- John Mantsch
- Erfahrung
